RT Journal Article
T1 COVID-19 in transplant recipients: The Spanish experience.
A1 Coll, Elisabeth
A1 Fernandez-Ruiz, Mario
A1 Sanchez-Alvarez, J Emilio
A1 Martinez-Fernandez, Jose R
A1 Crespo, Marta
A1 Gayoso, Jorge
A1 Bada-Bosch, Teresa
A1 Oppenheimer, Federico
A1 Moreso, Francesc
A1 Lopez-Oliva, Maria O
A1 Melilli, Edoardo
A1 Rodriguez-Ferrero, Marisa L
A1 Bravo, Carlos
A1 Burgos, Elena
A1 Facundo, Carme
A1 Lorenzo, Inmaculada
A1 Yañez, Iñigo
A1 Galeano, Cristina
A1 Roca, Ana
A1 Cabello, Mercedes
A1 Gomez-Bueno, Manuel
A1 Garcia-Cosio, MªDolores
A1 Graus, Javier
A1 Llado, Laura
A1 de Pablo, Alicia
A1 Loinaz, Carmelo
A1 Aguado, Beatriz
A1 Hernandez, Domingo
A1 Dominguez-Gil, Beatriz
A1 Spanish Group for the Study of COVID-19 in Transplant Recipients, 
K1 antibiotic: antiviral
K1 clinical decision-making
K1 clinical research/practice
K1 complication: infectious
K1 infection and infectious agents - viral
K1 infectious disease
AB We report the nationwide experience with solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients diagnosed with coronavirus disease 2019 (COVID-19) in Spain until 13 July 2020. We compiled information for 778 (423 kidney, 113 HSCT, 110 liver, 69 heart, 54 lung, 8 pancreas, 1 multivisceral) recipients. Median age at diagnosis was 61 years (interquartile range [IQR]: 52-70), and 66% were male. The incidence of COVID-19 in SOT recipients was two-fold higher compared to the Spanish general population. The median interval from transplantation was 59 months (IQR: 18-131). Infection was hospital-acquired in 13% of cases. No donor-derived COVID-19 was suspected. Most patients (89%) were admitted to the hospital. Therapies included hydroxychloroquine (84%), azithromycin (53%), protease inhibitors (37%), and interferon-β (5%), whereas immunomodulation was based on corticosteroids (41%) and tocilizumab (21%). Adjustment of immunosuppression was performed in 85% of patients. At the time of analysis, complete follow-up was available from 652 patients. Acute respiratory distress syndrome occurred in 35% of patients. Ultimately, 174 (27%) patients died. In univariate analysis, risk factors for death were lung transplantation (odds ratio [OR]: 2.5; 95% CI: 1.4-4.6), age >60 years (OR: 3.7; 95% CI: 2.5-5.5), and hospital-acquired COVID-19 (OR: 3.0; 95% CI: 1.9-4.9).
PB Elsevier BV
YR 2020
FD 2020-10-9
LK http://hdl.handle.net/10668/16472
UL http://hdl.handle.net/10668/16472
LA en
NO Coll E, Fernández-Ruiz M, Sánchez-Álvarez JE, Martínez-Fernández JR, Crespo M, Gayoso J, et al.; Spanish Group for the Study of COVID-19 in Transplant Recipients. COVID-19 in transplant recipients: the Spanish experience. Am J Transplant. 2021 May;21(5):1825-1837
NO The Spanish group for the Study of COVID-19 in transplant recipients is a joint effort of the Spanish Organización Nacional deTrasplantes and the Spanish Society of Nephrology, that promotedthe national collection of data on transplant recipients with COVID19. The authors thank professionals from all Spanish centers for theprovision of data to both registries. This study received no funding.Many kidney transplant nephrologists are endorsed by the KidneyResearch Net, REDinREN (RD16/0009). M.F.R. holds a research contract “Miguel Servet” (CP 18/00073) from the Spanish Ministry ofScience and Innovation, Instituto de Salud Carlos III.
DS RISalud
RD Apr 6, 2025